Sign in

    Rick Miller

    Research Analyst at Cantor Fitzgerald

    Rick Miller is Vice President at Cantor Fitzgerald & Co., specializing in equity research and analysis across various sectors. He covers a portfolio of companies with a focus on quantitative research and strategic investment recommendations, leveraging his advanced academic background to deliver strong research performance. Joining Cantor Fitzgerald in the early 2020s, Miller previously completed doctoral studies at Princeton University, building a foundation in analytics before transitioning to investment banking. He holds a PhD from Princeton and is registered with FINRA, maintaining active securities licenses for professional practice.

    Rick Miller's questions to ABEONA THERAPEUTICS (ABEO) leadership

    Rick Miller's questions to ABEONA THERAPEUTICS (ABEO) leadership • Q1 2025

    Question

    Rick Miller of Cantor Fitzgerald asked about the specific factors that made Lurie Children's the first activated treatment center and sought details on the wound profiles of patients contacting the Abeona Assist hub.

    Answer

    Chief Commercial Officer Dr. Madhav Vasanthavada explained that patient selection for initial treatment slots depends on clinical manifestation and insurance type, with commercially insured patients likely having faster access. Regarding patient inquiries, he stated that callers represent a wide age spectrum and typically have large wounded body areas, though specific wound profiles are not collected by the hub. CEO Dr. Vish Seshadri added that they receive consolidated updates, not patient-specific health information.

    Ask Fintool Equity Research AI

    Rick Miller's questions to SELB leadership

    Rick Miller's questions to SELB leadership • Q3 2022

    Question

    Rick Miller from Cantor Fitzgerald asked about promising signals from preclinical models of ImmTOR-IL regarding long-term follow-up post-dosing and inquired about the key criteria for selecting future autoimmune indications beyond having a known auto-antigen.

    Answer

    Chief Scientific Officer Takashi Kishimoto highlighted ESGCT data showing ImmTOR plus an engineered IL-2 mitigated immune responses out to Day 131. President and CEO Carsten Brunn added that while the platform has broad applicability, the initial focus for new indications is on liver-directed autoimmune diseases like PBC, where ImmTOR naturally accumulates.

    Ask Fintool Equity Research AI